HealthPharma & Biotech
Avacta Group PLC

Avacta soars after signing partnership deal with Korea's LG Group

The Affimer technology is Avacta's proprietary alternative to antibodies with wide applications in the life sciences for drug development, diagnostics and research tools

The development partnership and licence agreement is with LG Chem Life Sciences, part of the South Korean LG Group

Avacta Group PLC (LON: AVCT) shares soared on Monday after the firm said it has agreed on a development partnership and licence agreement with South Korea’s LG Group to develop Affimer therapeutics in several disease areas.

The AIM-listed developer of Affimer biotherapeutics and reagents said the multi-target therapeutics development agreement provides for upfront and near-term milestone payments, plus longer-term clinical development milestones totalling US$180 million.

WATCH: Avacta Group PLC signs first significant pharmaceutical licensing deal

Avacta will also receive royalties on any future product sales and LG Chem Life Sciences will cover Avacta's costs of research and development associated with the collaboration. Avacta may receive an additional US$130 million in option fees and milestone payments should LG elect to exercise its options for additional targets.

Avacta will generate and carry out early-stage optimisation of Affimer drug candidates against multiple undisclosed targets. LG Chem and Avacta will work together to move these candidates through to drug candidate selection, with LG Chem responsible for pre-clinical and regulatory studies, clinical development and worldwide marketing of any resulting products.

Strong validation of Affimer platform

Alastair Smith, the chief executive officer of Avacta Group, said the partnership with LG Chem was a strong validation of the Affimer platform.

"This alliance is an exciting opportunity, not only to work with a partner who has first-class biologics manufacturing and clinical development capabilities, but who also has a pioneering vision to develop innovative therapies,” Smith said.

"This landmark agreement with LG Chem reflects the substantial progress that we have made in developing the Affimer technology as a therapeutic platform and I look forward to updating the market on future progress and other partnerships," he added.

In afternoon trading, Avacta shares topped the London market gainers board, up 35.8% at 31.50p.

In a note to clients, analysts at ‘house’ broker finnCap said: “Not only is this a significant endorsement of the therapeutic potential of Affimers, but it provides additional near-term cash to help progress its lead oncology programme, which is targeted to enter the clinic in 2020.”

They added: “With a rich pipeline of interest in the reagent portfolio and ongoing discussions with other pharma companies, we expect further licensing activity. We estimate the risk-adjusted NPV of this deal, based only on the potential milestones to be worth 12-17p. We retain a target price of 120p.”

 -- Adds analyst comment, updates share price --

Quick facts: Avacta Group PLC

Price: £0.21

Market: AIM
Market Cap: £24.39 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...



Avacta Plc's therapeutics business 'has huge amount of potential' - analyst...

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space. The group's reported interim results to January 2019 today, revealing revenues of...

on 9/4/19

2 min read